News/ News/ Oncology David Hung’s Nuvation Bio seals merger with blank cheque firm Panacea Phil Taylor David Hung, immuno-oncology, M&A, Nuvation Bio, Oncology 0 Comment Two years after quietly forming cancer start-up Nuvation Bio, ex-Axovant and Medivation CEO David Hung has agreed a Share X David Hung’s Nuvation Bio seals merger with blank cheque firm Panacea https://pharmaphorum.com/news/david-hungs-nuvation-bio-seals-merger-with-blank-cheque-firm-panacea/
David Hung, immuno-oncology, M&A, Nuvation Bio, Oncology
0 Comment
